期刊文献+

难治性抑郁症患者MECT治疗前后血清VEGF水平的变化 被引量:3

Alteration of serum VEGF level after MECT treatment in patients with treatment resistant depression
下载PDF
导出
摘要 目的探讨难治性抑郁症(TRD)患者血清血管内皮生长因子(VEGF)水平在改良电抽搐治疗(MECT)治疗前后的变化情况。方法采用酶联免疫吸附法检测26例TRD患者MECT治疗前后及27例正常对照者的血清VEGF浓度;采用汉密尔顿抑郁量表17项(HAMD-17)评估TRD患者的临床症状。组间血清VEGF浓度比较采用Wilcoxon符号秩和检验,治疗前后血清VEGF浓度变化与HAMD总评分的相关性分析使用Speaman秩相关。结果 TRD患者MECT治疗后24例(92.3%)达到治疗有效标准。TRD组MECT治疗前血清VEGF水平与对照组差异无统计学意义(P>0.05);MECT治疗后血清VEGF水平有升高趋势,但差异无统计学意义(P>0.05)。治疗前后血清VEGF浓度与HAMD总评分变化的相关性有统计学意义(r=-0.663,P<0.01)。结论血清VEGF水平变化可能对临床疗效的评估有一定参考价值。 Objective To investigate the changes of serum VEGF after MECT treatment in TRD patients. Methods Twenty - six TRD patients who completed MECT treatment and twenty - seven healthy volunteers were enrolled in current study. Serum VEGF levels were measured by ELISA. Clinical symptoms were evaluated with HAMD - 17. Wilcoxon Rank Sum Test was applied on the differences between TRD patients and healthy volunteers of serum VEGF concentration, as well as the differences before and after MECT I! treatment in TRD. Spearmen correlation was applied to analyze the association between changes of serum VEGF 'concentration and total HAMD scores. Results Of 24 ( 92.3% ) patients had symptom relieves after MECT treatment. In comparison to lore - treatment, TRD patients serum VEGF level was not significantly different from healthy volunteers ( P 〉 0.05 ). TRD patients Serum VEGF level after MECT treatment exhibited tendency of increase, which was not significant(P 〉 0.05 ). The relationship between the changes of serum VEGF level and total HAMD scores were significant ( r = - 0. 663, P 〈 0.01 ). Conclusion The result indicated that serum VEGF level might be a useful index for clinical evaluation in antidepressant treatment.
出处 《四川精神卫生》 2014年第4期324-327,共4页 Sichuan Mental Health
基金 国家自然科学基金面上项目(81371506) 广东省自然科学基金博士启动项目(S2013040012414)
关键词 改良电抽搐治疗 难治性抑郁症 血管内皮生长因子 汉密尔顿抑郁量表 Modified electra convulsive therapy Treatment resistant depression Vascular endothelial growth factor Hamiltondepression scale
  • 相关文献

参考文献19

  • 1Plouet J, Moro F, Bertagnolli S, et al. Extracellular cleavage of the vascular endothelial growth factor189 - amino acid form by u- rokinase is required for its mitogenic effect [ J 3. J Biol Chem, 1997, 272(20) : 13390 - 13396.
  • 2Greenberg DA, Jin K. Experiencing VEGF [ J ]. Nat Genet, 2004, 36(8) :792 -793.
  • 3Schanzer A, Wachs FP, Wilhelm D, et al. Directstimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascularendo- thelial growth factor[ J ]. Brain Patho1,2004,14(3 ) :237 - 248.
  • 4Storkebaum E, Lambrechts D, Carmeliet P. VEGF : once regarded as a specific angiogenicfactor, now implicated in neuroprotection [ J ]. Bioessays,2004,26 (9) :943 - 954.
  • 5Warner - Schmidt JL, Duman RS. VEGF as a potential target for therapeutic intervention in depression [ J ]. Curr Opin Pharmacol, 2008,8(1) :14 -19.
  • 6Kosel M, Berney A. Treatment resistant depression: therapy and novel neuromodulatory treatments [ J ]. Rev Med Suisse, 2012,8 (339) :942 -945.
  • 7孙学礼.难治性抑郁障碍及其药物治疗[J].中国处方药,2006(10):9-13. 被引量:10
  • 8Zheng YP, Zhao JP, Phillips M, et al. Validity and reliability of the Chinese Hamilton Depression Rating Scale [ J]. Br J Psychia- try, 1988,152:660 - 664.
  • 9陈海莹,李华芳,况伟宏,赵靖平,谢世平,陶明,谭庆荣,顾牛范.艾司西酞普兰治疗抑郁症的随机双盲对照试验[J].上海精神医学,2010,22(5):300-303. 被引量:19
  • 10Minelli A, Zanardini R, Abate M, et al. Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients[J]. Prog Neuropsy- chopharmacol Bid Psychiatry ,2011,35 (5) : 1322 - 1325.

二级参考文献9

  • 1Yevtushenko VY,Belous AI,Yevtushenko YG,et al.Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder; a 6-week,multicenter,prospective,randomized,double-blind,active-controled study in adult outpatients.Clin Ther,2007,29(11):2319-2332.
  • 2Brunoni AR,Fraguas R,Fregni F.Pharmacological and combined interventions for the acute depressive episode:focus on efficacy and tolerability.Ther Clin Risk Manag,2009,5:897-910.
  • 3Montgomery SA,Loft H,Sánchez C,et al.Escitalopram (S-enantiomer of citalopram):clinical efficacy and onset of action predicted from a rat model.Pharmacol Toxicol,2001,88(5):282-286.
  • 4Owens MJ,Knight DL,Nemeroff CB.Second-generation SSRIs:human monoamine transporter binding profile of escitalopram and R-fluoxetine.Biol Psychiatr,2001,50(5):345-350.
  • 5Sánchez C,Bergqvist PB,Brennum LT,et al.Escitalopram,the S-(+)-enantiomer of citalopram,is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.Psychopharmacology,2003,167(4):353-362.
  • 6Lam RW,Andersen HF.The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder:an extended analysis.Pharmacopsychiatry,2006,39(5):180-184.
  • 7Cipriani1 A,Santilli C,Furukawa TA,et al.Escitalopram versus other antidepressive agents for depression.Cochrane Database Sys Rev,2009,2:CD006532.
  • 8Cipriani A,Furukawa TA,Salanti G,et al.Comparative efficacy and acceptability of 12 new-generation antidepressants:a multiple-treatments meta-analysis.Lancet,2009,373(9665):746 -758.
  • 9赵宏,蒋乃谦,商月娇.艾司西酞普兰与氢溴酸西酞普兰治疗抑郁症的对照观察[J].中国医院用药评价与分析,2008,8(9):693-695. 被引量:7

共引文献27

同被引文献62

  • 1Howell K R, Kutiyanawalla A, Pillai A, et al. Long-term continuous corticosterone treatment decreases VEGF receptor-2 expression in frontal cortex[J]. PLoS One, 2011,6(5): e20198.
  • 2Galecki P, Orzechowska A, Berent D, et al. Vascular endothelial growth factor receptor 2 gene(KDR) polymorphisms and expres- sion levels in depressive disorder[J]. J Affect Disord, 2013, 147 (1-3): 144-149.
  • 3Berent D, Macander M, Szemraj J, et al. Vascular endothelial growth factor A gene expression level is higher in patients with major depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment with statins[J]. Acta Neurobiol Exp (Wars), 2014, 74(1): 82-90.
  • 4Clark-Raymond A, Meresh E,Hoppensteadt D, et al.Vascular En-dothelial Growth Factor: A potential diagnostic biomarker for ma- jor depression[J]. J Psychiatr Res, 2014,59:22.
  • 5Effving B, Buttenschon H N, Foldager L, et al.Depression and BML influences the serum vascular endothelial growth factor level[J]. I nt J Neuropsychopharmacol, 2014,17(9): 1409-1417.
  • 6Lee B H, Kim Y K. Increased plasma VEGF levels in major de- pressive or manic episodes in patients with mood disorders[J]. J Affect Disord, 2012,136(1-2): 181-184.
  • 7Kotan Z, Sarandol E, Kirhan E, et al. Serum brain-derived neu- rotrophic factor, vascular endothelial growth factor and leptin lev- els in patients with a diagnosis of severe major depressive disor- der with melancholic features[J]. Ther Adv Psychopharmacol, 2012, 2(2): 65-74.
  • 8Isung J, Mobarrez F, Nordstrom P, et al. Low plasma vascular endothelial growth factor(VEGF) associated with completed sui- cide[J]. World J Biol Psychiatry, 2012, 13(6): 468-473.
  • 9Clark-Raymond A, Halaris A. VEGF and depression: a compre- hensive assessment of clinical data[J]. J Psychiatr Res, 2013, 47 (8): 1080-1087.
  • 10Murphy B P, Pang T Y, Hannan A J, et al. Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiap- ine treated first-episode psychosis[J]. Schizophr Res Treat- ment, 2014, 2014: 719395.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部